| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(06)70623-4 |
| P698 | PubMed publication ID | 16574546 |
| P2093 | author name string | Chao A Hsiung | |
| Wing-Yiu Lui | |||
| Su-Shun Lo | |||
| Anna Fen-Yau Li | |||
| Jacqueline Whang-Peng | |||
| Chew-Wun Wu | |||
| Jen-Hao Chen | |||
| Mao-Chin Hsieh | |||
| P2860 | cites work | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer | Q36001259 | ||
| Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group | Q36619190 | ||
| Complications following D3 gastrectomy: post hoc analysis of a randomized trial | Q44404665 | ||
| Stage migration influences on stage-specific survival comparison between D1 and D3 gastric cancer surgeries | Q44727634 | ||
| A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. | Q44911653 | ||
| Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer | Q45119980 | ||
| Japanese Classification of Gastric Carcinoma - 2nd English Edition - | Q51050338 | ||
| Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial | Q60716217 | ||
| Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial | Q62628706 | ||
| Use of a modified Foley catheter for continuous irrigation of intra-abdominal abscess | Q67991912 | ||
| Progress in gastric cancer surgery in Japan and its limits of radicality | Q69254536 | ||
| Node dissection in gastric cancer | Q69418495 | ||
| Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries | Q72354130 | ||
| Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients | Q72633352 | ||
| Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer | Q73077224 | ||
| Extended lymph-node dissection for gastric cancer | Q74629358 | ||
| Factors correlated with number of metastatic lymph nodes in gastric cancer | Q77957929 | ||
| Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501 | Q80204606 | ||
| P433 | issue | 4 | |
| P921 | main subject | randomized controlled trial | Q1436668 |
| P304 | page(s) | 309-315 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Nodal dissection for patients with gastric cancer: a randomised controlled trial | |
| P478 | volume | 7 |
| Q95360533 | Q95360533 |
| Q95360694 | Q95360694 |
| Q31125157 | 'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic Review |
| Q33854972 | A High Lymph Node Yield is Associated with Prolonged Survival in Elderly Patients Undergoing Curative Gastrectomy for Cancer: A Dutch Population-Based Cohort Study |
| Q35904118 | A decade in gastric cancer curative surgery: Evidence of progress (1999-2009). |
| Q34634079 | A meta-analysis of D1 versus D2 lymph node dissection. |
| Q34141623 | A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy |
| Q80496979 | A report on the First Asia-Pacific Gastric Cancer Conference |
| Q37468843 | Accomplishments in 2008 in the management of localized gastric cancer |
| Q37770081 | Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies |
| Q47118025 | Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery |
| Q86826431 | Adjuvant and neoadjuvant therapy for gastric cancer |
| Q34634936 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial |
| Q42695547 | Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial |
| Q26774528 | Advanced gastric cancer: What we know and what we still have to learn |
| Q64962997 | Advanced gastric cancer: the value of surgery. |
| Q38982209 | Advances in Laparoscopic and Robotic Gastrectomy for Gastric Cancer |
| Q37537123 | Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers |
| Q36262343 | Advances in the management of gastric cancer |
| Q37852579 | An evidence-based review of the surgical treatment of gastric adenocarcinoma |
| Q63367375 | Cancérologie digestive : pratiques chirurgicales |
| Q37697557 | Clinical significance of lymph node metastasis in gastric cancer |
| Q26766698 | Clinical significance of lymphadenectomy in patients with gastric cancer |
| Q90730116 | Clinical, Histological and Prognosis Correlations in Diagnosis and Treatment of Gastric Cancer |
| Q48071846 | Clinicopathological Variation of Lauren Classification in Gastric Cancer |
| Q90704144 | Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer |
| Q53618464 | Comparative effectiveness in esophagogastric cancer. |
| Q38663472 | Comparison of short- and long-term outcomes of laparoscopic vs open resection for gastric gastrointestinal stromal tumors |
| Q34434973 | Comparison of the operative outcomes and learning curves between laparoscopic and robotic gastrectomy for gastric cancer |
| Q36083593 | Comparisons of Gastric Cancer Treatments: East vs. West |
| Q64943276 | Compliance to D2 lymphadenectomy in laparoscopic gastrectomy. |
| Q81478906 | Continuing debate on D2 lymphadenectomy for gastric cancer |
| Q35898294 | Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy. |
| Q34995048 | Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy |
| Q37157335 | Current status of chemoradiotherapy for gastric cancer in Japan |
| Q38319561 | Current status of management of malignant disease: current management of gastric cancer |
| Q26863293 | D1 versus D2 lymphadenectomy for gastric cancer |
| Q36643077 | D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy |
| Q83464627 | D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery |
| Q83017427 | D3 or not D3... that is not the question |
| Q52683915 | Diagnostic evaluation of sentinel lymph node biopsy using indocyanine green and infrared or fluorescent imaging in gastric cancer: a systematic review and meta-analysis. |
| Q37141671 | Diverse eastern and Western approaches to the management of gastric cancer. |
| Q81564217 | Do we need a "three-star" hospital to cure a gastric cancer? |
| Q33611322 | Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference |
| Q39241462 | Does a Higher Cutoff Value of Lymph Node Retrieval Substantially Improve Survival in Patients With Advanced Gastric Cancer?-Time to Embrace a New Digit |
| Q87128832 | Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience |
| Q34405180 | Effect of somatostatin in advanced gastric cancer after D2 radical gastrectomy |
| Q49199109 | Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center |
| Q36897944 | Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer |
| Q37246927 | Evaluation of rational extent lymphadenectomy for local advanced gastric cancer |
| Q51746599 | Evaluation of the Role of Circulating Long Non-Coding RNA H19 as a Promising Novel Biomarker in Plasma of Patients with Gastric Cancer. |
| Q33912865 | Evolution in the surgical management of gastric cancer: is extended lymph node dissection back in vogue in the USA? |
| Q26800355 | Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine |
| Q26741508 | Evolution of gastric surgery techniques and outcomes |
| Q84088565 | Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? |
| Q43793742 | Extended lymphadenectomy in gastric cancer is crucial |
| Q45130356 | Extended lymphadenectomy in gastric cancer is debatable |
| Q47135872 | Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database |
| Q24187911 | Extent of lymph node dissection for adenocarcinoma of the stomach |
| Q37697546 | Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer |
| Q41662339 | Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden |
| Q55357371 | Favoring D2-Lymphadenectomy in Gastric Cancer. |
| Q93072438 | Fluorescent Lymphography-Guided Lymphadenectomy During Robotic Radical Gastrectomy for Gastric Cancer |
| Q48328295 | Gastrectomy with Extended Lymphadenectomy: a North American Perspective |
| Q42876512 | Gastric Cancer Working Group Report |
| Q39343374 | Gastric adenocarcinoma. |
| Q50071340 | Gastric and Small Bowel Tumors |
| Q99622843 | Gastric cancer |
| Q84276928 | Gastric cancer |
| Q26766091 | Gastric cancer: Current status of lymph node dissection |
| Q37828465 | Gastric cancer: surgery in 2011. |
| Q36216823 | Gastric carcinoma in China: Current status and future perspectives (Review) |
| Q54318808 | Gastrointestinal cancer: Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. |
| Q37824622 | Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications |
| Q89953715 | Historical assumptions of lymphadenectomy |
| Q83016338 | How does extended lymphadenectomy influence practical care for patients with gastric cancer? |
| Q42371509 | Identification of circulating microRNA signatures as potential noninvasive biomarkers for prediction and prognosis of lymph node metastasis in gastric cancer |
| Q48469163 | Impact of body mass index on postoperative outcome of advanced gastric cancer after curative surgery |
| Q92137906 | Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis |
| Q51032348 | Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. |
| Q83719669 | Improving outcome for scirrhous gastric cancer |
| Q26996589 | Improving the outcomes in gastric cancer surgery |
| Q91610760 | Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer-an east and west multicenter study |
| Q43760665 | Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer: results of a randomized controlled trial |
| Q47366670 | Influence of excess body weight on the surgical outcomes of total gastrectomy |
| Q42641584 | Initial experience of robotic gastrectomy and comparison with open and laparoscopic gastrectomy for gastric cancer |
| Q33860465 | Intraoperative radiotherapy: review of techniques and results. |
| Q83379639 | Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial |
| Q42834551 | Is lymphadenectomy a predictor or savior for patients with gastric cancer? |
| Q64076485 | Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach |
| Q53151183 | Laparoscopic gastrectomy: advances enable wide clinical application. |
| Q46845983 | Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study |
| Q51889808 | Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case-control study. |
| Q59678116 | Locoregional control remains a critical issue in gastric cancer |
| Q38493106 | Lymph node dissection for gastric cancer: a critical review. |
| Q40584507 | Lymph node dissection in curative gastrectomy for advanced gastric cancer |
| Q37785829 | Lymph node dissection in the resection of gastric cancer: Review of existing evidence |
| Q37132729 | Lymph node metastasis of gastric cancer |
| Q83915546 | Lymphadenectomy in cancer: time for a paradigm shift? |
| Q89312962 | Lymphadenectomy in elderly/high risk patients: should it be different? |
| Q26752009 | Lymphadenectomy in gastric cancer: Contentious issues |
| Q40407857 | Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study |
| Q89312954 | Lymphadenectomy: state of the art |
| Q44234766 | Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients |
| Q37475323 | MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2. |
| Q38157342 | Management of gastric cancer in Asia: resource-stratified guidelines |
| Q89953722 | Management of postoperative complications of lymphadenectomy |
| Q89225479 | Metastasis to the lymph nodes along the proper hepatic artery from adenocarcinoma of the stomach |
| Q33527555 | Metastatic lymph node in gastric cancer; is it a real distant metastasis? |
| Q64068157 | Modified American Joint Committee on Cancer Tumor-Node-Metastasis Staging System Based on the Node Ratio Can Further Improve the Capacity of Prognosis Assessment for Gastric Cancer Patients |
| Q26779725 | Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives |
| Q36494032 | More controversy than ever - challenges and promises towards personalized treatment of gastric cancer |
| Q92972956 | Multimodality management of locally advanced gastric cancer-the timing and extent of surgery |
| Q36009466 | N3 subclassification incorporated into the final pathologic staging of gastric cancer: a modified system based on current AJCC staging. |
| Q42596313 | National outcomes and uptake of laparoscopic gastrectomy for cancer in England |
| Q89863558 | Necessity of prophylactic splenic hilum lymph node clearance for middle and upper third gastric cancer: a network meta-analysis |
| Q48511305 | Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? |
| Q84107296 | New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points |
| Q37201999 | New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma |
| Q42200325 | Nomogram analysis and external validation to predict the risk of lymph node metastasis in gastric cancer |
| Q36304275 | Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative |
| Q26744183 | On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer |
| Q88423801 | Oncological outcomes of function-preserving gastrectomy for early gastric cancer: a multicenter propensity score matched cohort analysis comparing pylorus-preserving gastrectomy versus conventional distal gastrectomy |
| Q41452357 | Overall Survival Is Impacted by Birthplace and Not Extent of Surgery in Asian Americans with Resectable Gastric Cancer |
| Q34191950 | Overexpression of miR-370 and downregulation of its novel target TGFβ-RII contribute to the progression of gastric carcinoma |
| Q43166535 | Palliative resection in noncurative gastric cancer patients |
| Q51740178 | Patterns of surveillance following curative intent therapy for gastroesophageal cancer. |
| Q37522736 | Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04- |
| Q33413548 | Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer |
| Q40236143 | Pilot series of robot-assisted laparoscopic subtotal gastrectomy with extended lymphadenectomy for gastric cancer |
| Q36909388 | Poor prognosis of advanced gastric cancer with metastatic suprapancreatic lymph nodes |
| Q24198252 | Post-surgical chemotherapy versus surgery alone for resectable gastric cancer |
| Q37651342 | Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice |
| Q26738505 | Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis |
| Q34851939 | Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis |
| Q43461521 | Postoperative pancreatic fistula formation according to ISGPF criteria after D2 gastrectomy in Western patients |
| Q26744362 | Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer |
| Q38824375 | Potentially Curable Cancers of the Esophagus and Stomach. |
| Q34255463 | Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer |
| Q97570237 | Prognosis and clinicopathologic features in patients with gastric stump cancer after curative surgery |
| Q36328902 | Prognostic Value of Metastatic No.8p LNs in Patients with Gastric Cancer |
| Q44501869 | Prognostic impact of lymph node retrieval and ratio in gastric cancer: a U.S. single center experience |
| Q36316680 | Prognostic significance of distal subtotal gastrectomy with standard D2 and extended D2 lymphadenectomy for locally advanced gastric cancer |
| Q55402125 | Prognostic significance of suprapancreatic lymph nodes and its implication on D2 dissection. |
| Q38613676 | Prognostic significance of the total number of harvested lymph nodes for lymph node-negative gastric cancer patients. |
| Q36303653 | Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. |
| Q36608800 | Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial |
| Q26774542 | Quality of life: A critical outcome for all surgical treatments of gastric cancer |
| Q42732352 | R0 resection in the treatment of gastric cancer: room for improvement. |
| Q44551895 | Race and correlations between lymph node number and survival for patients with gastric cancer |
| Q34137266 | Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique? |
| Q41913078 | Radical D2 gastrectomy for cancer. The case of D2 resections |
| Q81234925 | Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer |
| Q37353926 | Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer |
| Q37524936 | Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. |
| Q58605480 | Reporting of outcomes in gastric cancer surgery trials: a systematic review |
| Q26769955 | Robot-assisted surgery for gastric cancer |
| Q42631010 | Robotic gastrectomy for gastric cancer: surgical techniques and clinical merits |
| Q41201656 | S-l combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial |
| Q48388675 | SIRT3 expression as a biomarker for better prognosis in gastric cancer |
| Q36392301 | Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients |
| Q53357274 | Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer. |
| Q50469225 | Sentinel node mapping during laparoscopic distal gastrectomy for gastric cancer. |
| Q35555487 | Significance of lymph node metastasis in cancer dissemination of head and neck cancer |
| Q91654832 | Significance of nodal dissection and nodal positivity in gastric cancer |
| Q43801555 | Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery |
| Q51784524 | Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. |
| Q33688976 | Simultaneous sentinel lymph node computed tomography and locoregional chemotherapy for lymph node metastasis in rabbit using an iodine-docetaxel emulsion |
| Q37697553 | Somatic alterations in mitochondrial DNA and mitochondrial dysfunction in gastric cancer progression |
| Q64118903 | Staging of gastric cancer with the Clinical Stage Prediction score |
| Q30577032 | Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893] |
| Q39826656 | Surgeons' knowledge of quality indicators for gastric cancer surgery |
| Q37191090 | Surgery and adjuvant chemotherapy |
| Q40985835 | Surgical and Survival Outcome Following Truly Palliative Gastrectomy in Patients with Incurable Gastric Cancer |
| Q36373630 | Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer |
| Q84866085 | Surgical impact on gastric cancer with locoregional invasion |
| Q34962070 | Surgical management of gastric cancer: the East vs. West perspective |
| Q62628533 | Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial |
| Q54695199 | Survival benefit of "D2-plus" gastrectomy in gastric cancer patients with duodenal invasion. |
| Q36464425 | Survival prognosis and clinicopathological features of the lymph nodes along the left gastric artery in gastric cancer: implications for D2 lymphadenectomy |
| Q26771399 | Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly |
| Q41845256 | TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway |
| Q64230121 | Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon |
| Q80496953 | The beginning of a new era: East meets West more comfortably regarding lymphadenectomy for gastric cancer. Japan will finally drop the surgery-alone arm in its pursuit of a multimodal treatment strategy |
| Q41911966 | The correlation between miRNA and lymph node metastasis in gastric cancer |
| Q37803170 | The extent of lymph node dissection for gastric cancer: A critical appraisal |
| Q33608236 | The prognostic value of lymph nodes dissection number on survival of patients with lymph node-negative gastric cancer. |
| Q41242836 | The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors |
| Q57069583 | Therapeutic Value of Lymph Node Dissection Along the Superior Mesenteric Vein and the Posterior Surface of the Pancreatic Head in Gastric Cancer Located in the Lower Third of the Stomach |
| Q34493523 | Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment |
| Q26778029 | Towards curative therapy in gastric cancer: Faraway, so close! |
| Q44833405 | Treatment of patients with stage IV gastric cancer |
| Q35688584 | Treatment of resectable gastric cancer |
| Q41097111 | Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer |
| Q42317061 | Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy |
| Q90319010 | Tumor progression-dependent angiogenesis in gastric cancer and its potential application |
| Q38002415 | Update of adjuvant chemotherapy for resected gastric cancer |
| Q43472644 | Validation of limited lymphadenectomy for lower-third gastric cancer based on depth of tumour invasion |
| Q36747834 | Vascularizing lymph node dissection for advanced gastric cancer: A single-institution experience |
| Q39929793 | Worldwide practice in gastric cancer surgery |
| Q80337130 | [Importance of anesthesia in multimodal oncologic therapeutical concepts] |
| Q88159910 | [Is D2 and D1 lymphadenectomy for patients with gastric cancer beneficial?] |
| Q84563991 | [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint] |
| Q82526784 | [Tumors of the upper gastro-intestinal tract] |
| Q41412761 | miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer |
| Q33653161 | miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma |
Search more.